Inhalable liposomes for treating lung diseases: clinical development and challenges
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhalable liposomes for treating lung diseases: clinical development and challenges
Authors
Keywords
-
Journal
Biomedical Materials
Volume 16, Issue 5, Pages 054101
Publisher
IOP Publishing
Online
2021-06-17
DOI
10.1088/1748-605x/ac0c0c
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overcoming barriers by local drug delivery with liposomes
- (2021) S.G. Antimisiaris et al. ADVANCED DRUG DELIVERY REVIEWS
- Inhalation delivery technology for genome-editing of respiratory diseases
- (2020) Michael Y.T. Chow et al. ADVANCED DRUG DELIVERY REVIEWS
- Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery
- (2020) Andrew M. Shen et al. JOURNAL OF CONTROLLED RELEASE
- Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges
- (2020) Ling Ding et al. JOURNAL OF CONTROLLED RELEASE
- Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
- (2019) Charles S Haworth et al. Lancet Respiratory Medicine
- Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
- (2019) Matt Shirley DRUGS
- Inhaled Cisplatin for NSCLC: Facts and Results
- (2019) Christoforos Kosmidis et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Challenges and strategies in drug delivery systems for treatment of pulmonary infections
- (2019) Duy-Khiet Ho et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- The role of liposomes in clinical nanomedicine development. What now? Now what?
- (2019) Daan J.A. Crommelin et al. JOURNAL OF CONTROLLED RELEASE
- Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study
- (2018) David E Griffith et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pulmonary surfactant and drug delivery: Focusing on the role of surfactant proteins
- (2018) Roberta Guagliardo et al. JOURNAL OF CONTROLLED RELEASE
- Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges
- (2016) Shadabul Haque et al. Nanomedicine-Nanotechnology Biology and Medicine
- Development of Liposomal Ciprofloxacin to Treat Lung Infections
- (2016) David Cipolla et al. Pharmaceutics
- Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life
- (2015) Ga-Lai M. Chong et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology ofAspergillusspp. infection in lung transplantation
- (2015) Maddalena Peghin et al. TRANSPLANT INTERNATIONAL
- Interleukin-2: Biology, Design and Application
- (2015) Natalia Arenas-Ramirez et al. TRENDS IN IMMUNOLOGY
- Liposomal siRNA nanocarriers for cancer therapy
- (2014) Bulent Ozpolat et al. ADVANCED DRUG DELIVERY REVIEWS
- Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients
- (2014) C Posch et al. BRITISH JOURNAL OF CANCER
- Nanoparticle-Mediated Pulmonary Drug Delivery: A Review
- (2014) Mukta Paranjpe et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant
- (2013) Victor Monforte et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Differential Uptake of Nanoparticles and Microparticles by Pulmonary APC Subsets Induces Discrete Immunological Imprints
- (2013) C. L. Hardy et al. JOURNAL OF IMMUNOLOGY
- Phase II studies of nebulised Arikace in CF patients withPseudomonas aeruginosainfection
- (2013) J P Clancy et al. THORAX
- Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
- (2013) David J Serisier et al. THORAX
- Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung
- (2012) Alexander J. Chou et al. PEDIATRIC BLOOD & CANCER
- Prophylactic Application of Nebulized Liposomal Amphotericin B in Hematologic Patients with Neutropenia
- (2011) Annette Hullard-Pulstinger et al. ONKOLOGIE
- Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation
- (2010) Víctor Monforte et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection
- (2009) O. O. Okusanya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lung Deposition of a Liposomal Cyclosporine A Inhalation Solution in Patients after Lung Transplantation
- (2009) Juergen Behr et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Nebulized Liposomal Amphotericin B Prophylaxis for Aspergillus Infection in Lung Transplantation: Pharmacokinetics and Safety
- (2009) Víctor Monforte et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Aerosolized Liposomal Amphotericin B for the Prevention of Invasive Pulmonary Aspergillosis during Prolonged Neutropenia: A Randomized, Placebo‐Controlled Trial
- (2008) Bart J. Rijnders et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
- (2008) Daryl C. Drummond et al. JOURNAL OF PHARMACEUTICAL SCIENCES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started